Hyperprolactinemia with Prolactinoma: What to Do After Dopamine Agonist Therapy Fails

Clinical Scenario

This protocol applies to symptomatic patients with a prolactin-secreting pituitary microadenoma or macroadenoma in whom the standard first-line approach — escalating dopamine agonist therapy — has not achieved adequate disease control.

Previous Treatment — Failure Condition

The preceding line involved stepwise escalation of dopamine agonist therapy, including switching from bromocriptine to cabergoline in bromocriptine-resistant patients. The targets for that line were normalization of serum prolactin levels and at least a 50% reduction in tumor size. This next-line protocol is indicated when those targets were not reached — whether due to drug resistance, intolerance, or both.

Next-Line Approach (Partial Overview)

For patients in whom dopamine agonist escalation has failed or cannot be tolerated, transsphenoidal surgery is among the approaches addressed in this protocol. The complete decision pathway — including which patients qualify, the sequencing of options, and how to manage specific tolerability issues — is available in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2010-1692

We recommend dopamine agonist therapy to lower prolactin levels, decrease tumor size, and restore gonadal function for patients harboring symptomatic prolactin-secreting microadenomas or macroadenomas.

We suggest that clinicians offer transsphenoidal surgery to symptomatic patients with prolactinomas who cannot tolerate high doses of cabergoline or who are not responsive to dopamine agonist therapy.

For patients who are intolerant of oral bromocriptine, intravaginal administration may be attempted.

View source ↗